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Aging-related tau astrogliopathy (ARTAG) is defined by the presence of two types of 
tau-bearing astrocytes: thorn-shaped astrocytes (TSAs) and granular/fuzzy astrocytes 
in the brain of old-aged individuals. The present study is focused on TSAs in rare forms 
of ARTAG with no neuronal tau pathology or restricted to entorhinal and transentorhinal 
cortices, to avoid bias from associated tauopathies. TSAs show 4Rtau phosphorylation 
at several specific sites and abnormal tau conformation, but they lack ubiquitin and 
they are not immunostained with tau-C3 antibodies which recognize truncated tau at 
Asp421. Astrocytes in ARTAG have atrophic processes, reduced glial fibrilary acidic 
protein (GFAP), and increased superoxide dismutase 2 (SOD2) immunoreactivity. Gel 
electrophoresis and western blotting of sarkosyl-insoluble fractions reveal a pattern of 
phospho-tau in ARTAG characterized by two bands of 68kDa and 64kD, and several 
middle bands between 35kDa and 50kDa which differ from what is seen in AD. 
Phosphoproteomics of dissected vulnerable regions identifies an increase of 
phosphorylation marks in a large number of proteins in ARTAG compared with 
controls. GFAP, aquaporin 4, several serine-threonine kinases, microtubule associated 
proteins, and other neuronal proteins are among the differentially phosphorylated 
proteins in ARTAG thus suggesting a hyper-phosphorylation background that affects 
several molecules, including many kinases and proteins from several cell 
compartments and various cell types. Finally, present results show for the first time that 
tau seeding is produced in neurons of the hippocampal complex, astrocytes, 
oligodendroglia and along fibers of the corpus callosum, fimbria, and fornix following 
inoculation into the hippocampus of wild type mice of sarkosyl-insoluble fractions 
enriched in hyper-phosphorylated tau from selected ARTAG cases. These findings 
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Aging-related tau astrogliopathy (ARTAG) is defined by the presence of two types of 
tau-bearing astrocytes: thorn-shaped astrocytes (TSAs) and granular/fuzzy astrocytes 
(GFAs) in the brain of old-aged individuals (28). TSAs are a variety of fibrillar astrocyte 
characterized by a thorn-like appearance, located in the subependymal and subpial 
regions, perivascular spaces, and in clusters in the frontal and temporal cortices, basal 
forebrain, and brain stem (16, 21, 22, 23, 30, 36, 37, 40, 49, 54). TSAs were first 
described in association with Alzheimer’s disease (AD) and argyrophilic grain disease 
(AGD) but they are also common in other tauopathies in the elderly (29, 31). GFAs are 
mainly located in the grey matter; firstly identified in a particular subgroup of patients 
with dementia in the elderly (30), they are also present in combination with other 
tauopathies in the elderly (14).  
TSAs in advanced stages of AD show tau phosphorylation at several specific sites and 
abnormal tau conformation, but they lack ubiquitin and are not immunostained with tau-
C3 antibodies which recognize truncated tau at Asp421 (37). Gel electrophoresis and 
western blotting to phospho-tau of sarkosyl-insoluble fractions from TSAs-containing 
white matter showed a pattern of two bands of 68kDa and 64 kDa typical of 4R-
taupathies in contrast with the phospho-tau band pattern of AD characterized by three 
bands of 68kDa, 64kDa, and 60kDa, and a lower band of truncated tau of about 20 kDa 
obtained from the neurofibrillary tangle (NFT)-rich dissected hippocampus of the same 
cases (37). Therefore, TSAs in AD are 4Rtau astrocytes with immunohistochemical 
properties of pre-tangles (14). 
Pioneering studies have demonstrated seeding and spreading of abnormal tau derived 
from brain homogenates of AD and other tauopathies inoculated into the brain of 
transgenic mice over-expressing human tau or mutated tau under the rationale that this 
background facilitates tau seeding and propagation (4, 7, 34). The characteristics of 
seeding differ depending on the type of tauopathy, thus suggesting that several types 
of tau species have particular properties (8, 41). Recent studies have shown seeding of 
human tau from homogenates of AD and tauopathy cases inoculated into the brain of 
wild-type mice, thereby indicating that a potentiating background is not mandatory to 
trigger this process (19, 41). All these experiments were performed using brain 
samples with tau pathology only in neurons, or in neurons and glial cells. None of these 
studies enabled the examination of glial tau as the source of abnormal tau seeding. 
This is an important aspect because neurodegenerative diseases are not restricted to 
neurons but rather involve neurons and glial cells (12, 44, 45, 58). 
 




The present study is designed to delve further into the characteristics of tau deposition, 
and the properties and environment of TSAs in ARTAG cases with maximal tau 
deposition limited to the entorhinal and transentorhinal cortex (Braak and Braak stages 
I-II  of NFT pathology) to avoid bias linked to associated tauopathies. The study is 
focused on four main aspects: i. biochemical characteristics of tau, ii. properties of 
TSAs, iii. assessment of the phosphoproteome and identification of phosphorylated 
proteins in TSA-enriched temporal white matter to characterize the biochemical 
environment in which TSAs develop, and iv. capacity of tau seeding of sarkosyl-
insoluble fractions from ARTAG cases inoculated into the hippocampus of wild-type 
mice, and identification of cell targets of tau seeding. 
  




Material and methods 
Brain samples 
Brain tissue was obtained from the Institute of Neuropathology HUB-ICO-IDIBELL 
Biobank following the guidelines of Spanish legislation on this matter (Real Decreto de 
Biobancos 1716/2011) and approval of the local ethics committee. One hemisphere 
was immediately cut in coronal sections, 1cm thick, and selected areas of the 
encephalon were rapidly dissected, frozen on metal plates over dry ice, placed in 
individual air-tight plastic bags, and stored at -80ºC until use for biochemical studies. 
The other hemisphere was fixed by immersion in 4% buffered formalin for 3 weeks for 
morphological studies; sections from twenty representative brain regions were stained 
with hematoxylin and eosin, periodic acid-Schiff (PAS) and Klüver-Barrera, or 
processed for immunohistochemistry for microglia Iba1, GFAP, β-amyloid, Aβ40, Aβ42, 
phospho-tau AT8, α-synuclein, TDP-43, ubiquitin, p62C and p62N, using EnVision+ 
System peroxidase (Dako), and diaminobenzidine and H2O2. Details of the antibodies 
are shown in Table I. 
NFT stages were categorized according to Braak and Braak modified for paraffin 
sections (5, 6). Since the present series of ARTAG was restricted to cases with no 
neuronal pathology or with NFTs and pre-tangles limited to the entorhinal and 
entorhinal cortex without β-amyloid deposition, the possibility that some cases had 
associated primary age-related tauopathy (PART) (9) cannot be excluded. Staging of 
argyrophilic grain disease (AGD) was established as reported elsewhere (16). Chronic 
traumatic encephalopathy (35) was not recorded in any case. 
Control cases had not suffered from neurologic or psychiatric diseases, infections of 
the nervous system, brain neoplasms, or systemic and central immune diseases, and 
did not have abnormalities in the neuropathological examination. Cases with 
associated pathologies such as vascular diseases (excepting mild atherosclerosis and 
arteriolosclerosis), TDP-43 proteinopathy, metabolic syndrome, and hypoxia were 
excluded from the present study.  
ARTAG cases were six men and two women aged 77 ± 8.6 years. ARTAG lesions 
were categorized as detailed elsewhere (31). Semi-quantitative assessment of optical 
microscopy sections was performed separately by at least two people. The abundance 
of THAs, as revealed in AT8-immunostained sections, was categorized as: ++ for large 
and + for small numbers of positive cells/inclusions, and – for no immunoreactivity. The 
characteristics of cases and the distribution of lesions in each case are summarized in 
Table II.  
Control cases were four men and four women aged 66.3 ± 5.5 years. In addition, the 
frontal cortex of two AD cases stages V-VI/C (one man aged 74 and one woman aged 




78) was used in the study of phospho-tau band patterns from sarkosyl-insoluble 
fractions. The cause of death in ARTAG and control cases was variable and included 
bronchopneumonia, respiratory failure, cardiac arrest, kidney failure, pulmonary 
thromboembolism, and metastatic carcinoma. Post-mortem delay between death and 
tissue processing was between 4h and 18h in ARTAG and control cases.    
All cases were used for immunohistochemistry, immunofluorescence and confocal 
microscopy, and RT-qPC. Cases 3 (medulla oblongata, basal forebrain), 5, and 7 
(basal forebrain and caudate) were used for the extraction of sarkosyl-insoluble 
fractions and western blotting studies of tau. Cases 2 (medulla oblongata), 3, and 6 
(temporal white matter) were used for phosphoproteomics.    
Sarkosyl-insoluble fractions used for inoculation were obtained from the medulla 
oblongata and basal forebrain of an 87-year-old women with PARTI (case 3); and from 
the basal forebrain and caudate of two men aged 75 and 70 years with 
neuropathological diagnoses of PART2 and Lewy body disease stage 3, respectively 
(cases 5 and 7) (Table II). 
Importantly, all the samples used for inoculation studies were first checked for 
morphological changes in cryostat sections stained with anti-tau antibodies. Although 
the preservation of the material was suboptimal due to freezing, it was suitable to verify 
the presence of large numbers of TSAs and the lack of tau pathology in other cell types 
including neurons (as expected from the screening and selection of cases in the 
present series) and oligodendrocytes.   
Control and ARTAG cases were processed in parallel in all assessments.  
Immunohistochemistry 
De-waxed sections, 4 microns thick, were processed for immunohistochemistry. The 
sections were boiled in citrate buffer (20min) to retrieve tau antigenicity. Endogenous 
peroxidases were blocked by incubation in 10% methanol-1% H2O2 solution (15min) 
followed by 3% normal horse serum solution. Then the sections were incubated at 4ºC 
overnight with one of the primary antibodies against 4Rtau, 3Rtau, amino acids 14-26 
(antibody 499), amino acids 229-233 (antibody 229), amino acids 394-398),  specific 
phospho-tau Thr181, Ser199, Thr231, Ser262 and Ser422, double-phosphorylation 
sites Ser202-Thr205 (clone AT8), Ser396-404 (PHF1) and Thr212-Ser214 (tau-100), 
conformational tau modifications at amino acids 5-15  (Alz50) and amino acids 312-322 
(MC-1), and tau truncated at aspartic acid 421 (tau-C3). Other sections were incubated 
with one of the following antibodies against glial fibrillary acidic protein (GFAP): P-
GFAP Ser8, phosphorylated tuberin (P-tuberin Ser939), superoxide dismutase 2 
(SOD2), aquaporine 4 (AQP4), phosphorylated p38 (p38-P Thr180-Tyr182), 
phosphorylated protein kinase A α/β (PKA-P α/β Thr197), glutamate transporter solute 




carrier family 1, member 2 (GLT-1/EAAT2), vimentin and YKL-40. The characteristics 
of the antibodies, dilutions, and suppliers are listed in Table I.  
Following incubation with the primary antibody, the sections were incubated with 
EnVision + system peroxidase (Dako, DK) for 30 min at room temperature. The 
peroxidase reaction was visualized with diaminobenzidine and H2O2. Control of the 
immunostaining included omission of the primary antibody; no signal was obtained 
following incubation with only the secondary antibody.  
Double-labeling immunofluorescence and confocal microscopy in human cases   
De-waxed sections, 4 microns thick, were stained with a saturated solution of Sudan 
black B (Merck, DE) for 15 min to block autofluorescence of lipofuscin granules present 
in cell bodies, and then rinsed in 70% ethanol and washed in distilled water. The 
sections were boiled in citrate buffer to enhance antigenicity and blocked for 30 min at 
room temperature with 10% fetal bovine serum diluted in PBS. Then, the sections were 
incubated at 4ºC overnight with combinations of primary antibodies against phospho-
tau Thr181, and antibodies 499 and 394; P-GFAP Ser8 and phospho-tau Thr181; and 
AT8 and SOD2, vimentin, YKL-40, P-tuberin, GLT-1, AQP4, p38-P Thr180-Tyr182, and 
P-PKA α/β Thr197.  
The characteristics of the antibodies, dilutions, and suppliers are listed in Table I.  
After washing, the sections were incubated with Alexa488 or Alexa546 (1:400, 
Molecular Probes, USA) fluorescence secondary antibodies against the corresponding 
host species. Nuclei were stained with DRAQ5TM (1:2,000, Biostatus, GB). After 
washing, the sections were mounted in Immuno-Fluore mounting medium (ICN 
Biomedicals, USA), sealed, and dried overnight. Sections were examined with a Leica 
TCS-SL confocal microscope. 
Image acquiring and analysis 
Confocal images were acquired using a microscope Leica DMIRE2 and Leica confocal 
software. Quantification of GFAP positive cell area and size was performed using Fiji 
ImageJ software in three different sections containing between 25-100 cells per image. 
Statistical Analysis 
Statistical analysis was performed using GraphPad Prismv5 software. Differences 
between groups were analyzed by one-way ANOVA followed by the appropriate post-
hoc test. 
Normalization of antibody-based protein detection 
Series of cases were processed in parallel to equalize the conditions of staining of a 
particular antibody in sections from different entities, and a given antibody was used in 
different series to minimize day-to-day variations. The estimation of co-localization of 
two proteins labeled with specific antibodies and examined with the confocal 




microscope was assessed by counting the number of cells expressing both antigens in 
relation to the number of cells stained with each one of the antibodies in five selected 
fields per section at a magnification of x600 in every case. In most instances, the 
values were expressed as the percentage of the more abundant protein because the 
less abundant protein represented a subset of the former.    
Western blotting of sarkosyl-insoluble fractions 
Frozen samples of about 1g were lysed in 10 volumes (w/v) with cold suspension 
buffer (10mM Tris-HCl, pH 7.4, 0.8M NaCl, 1mM EGTA) supplemented with 10% 
sucrose, protease, and phosphatase inhibitors (Roche, GE). The homogenates were 
first centrifuged at 20,000×g for 20min (Ultracentrifuge Beckman with 70Ti rotor) and 
the supernatant (S1) was saved. The pellet was re-homogenized in 5 volumes of 
homogenization buffer and re-centrifuged at 20,000×g for 20min (Ultracentrifuge 
Beckman with 70Ti rotor). The two supernatants (S1 + S2) were then mixed and 
incubated with 0.1% N-lauroylsarkosynate (sarkosyl) for 1h at room temperature while 
being shaken. Samples were then centrifuged at 100,000×g for 1h (Ultracentrifuge 
Beckman with 70Ti rotor). Sarkosyl-insoluble pellets (P3) were re-suspended (0.2 ml/g) 
in 50mM Tris–HCl (pH 7.4). Protein concentrations were quantified with the 
bicinchoninic acid assay (BCA) assay (Pierce, Waltham, MA). Samples were mixed 
with loading sample buffer and heated at 95ºC for 5min. 60ug of protein was separated 
by electrophoresis in SDS-PAGE gels and transferred to nitrocellulose membranes 
(200mA per membrane, 90 min). The membranes were blocked for 1h at room 
temperature with 5% non-fat milk in TBS containing 0.2% Tween and were then 
incubated with one of the primary antibodies: anti-tau Ser422 (diluted 1:1000; Thermo 
Fisher (Waltham, MA, USA), or anti-4Rtau (diluted 1:1,000; Millipore). After washing 
with TBS-T, blots were incubated with the appropriate secondary antibody (anti-
mouse/anti-rabbit IgG conjugated with horseradish peroxidase diluted at 1:2,000, 
DAKO, DE) for 45min at room temperature. Immune complexes were revealed by 
incubating the membranes with chemiluminescence reagent (Amersham, GE 
Healthcare, Buckinghamshire, UK).  
Phosphoproteomics 
Sample preparation, phosphopeptide enrichment, and LC-MSMS analysis  
Three control and three ARTAG fresh brain samples were processed for protein 
extraction in 7M urea, 2M thiourea, and 2% SDS. After that, samples were quantified 
using the BCA method and 350μg of every sample condition was digested using a 
FASP (Filter-Aided Sample Preparation) approach. Briefly, proteins were reduced with 
dithiothreitol 10mM (60min, 32ºC) and alkylated with iodoacetamide 20mM (30min at 
25ºC in the dark). Then, the samples were loaded onto an Amicon Ultra (filter 10KDa, 




0.5mL, Millipore, Billerica, MA, USA) device to remove interfering agents with 2 rounds 
of centrifugations/washes with 100mM ammonium bicarbonate buffer (13,600g; 25min 
at room temperature). Digestion was carried out in two steps: first, samples were 
digested (1:50w sample/w enzyme) with Lys-C (Wako, Richmond, VA, USA) in 6M 
urea buffer for 3h at 35ºC, second, the samples were diluted 10-fold 
with 100mM ammonium bicarbonate buffer and digested with modified porcine trypsin 
(Promega-Gold, Madison, WI, USA) (1/25w sample/w enzyme) for 16h at 37ºC. The 
resulting peptide mixture was recovered by centrifuging the filter. Then, the filter was 
washed twice with 300μL of 50mM ammonium bicarbonate and once with 200μL of 
20% acetonitrile/50mM ammonium bicarbonate (13,600g for 25min at room 
temperature). All the fractions were pooled, and the final peptide mixture was acidified 
with formic acid. Finally, the final volume of the acidified peptide solution was reduced 
on a SpeedVac vacuum system (Thermo Fisher Scientific, Barcelona, Spain), and the 
peptide solution was desalinated with a C18 spin column (Thermo Fisher Scientific) 
following the indications of the supplier. An aliquot of 200μg was separated and further 
processed for phosphopeptide enrichment.  
Phosphopeptide enrichment was carried out with titanium dioxide (TiO2) magnetic 
beads following the specifications of the supplier (High-Select™TiO2 Phosphopeptide 
Enrichment Kit, Thermo Fisher Scientific). Briefly, peptides were re-suspended by 
vortexing in 150μL of binding/equilibration buffer at pH <3. Then, the phosphopeptides 
were enriched with the TiO2 beads and finally dried in a SpeedVacunder vacuum. 
Samples were analyzed in a Proxeon 1000 liquid chromatographer coupled to an 
Orbitrap Fusion Lumos (Thermo Fisher Scientific) mass spectrometer. Samples were 
re-suspended in 0.5% formic acid in water, and 4.5l were injected for LC-MSMS 
analysis. Peptides were trapped on an NTCC-360/75-3-123 LC column and separated 
using a C18 reverse phase LC column-Easy Spray (Thermo Fisher Scientific). The 
gradient used for the elution of the peptides was 1% to 35% in 90min followed by a 
gradient from 35% to 85% in 10min with 250nL/min flow rate. Eluted peptides were 
subjected to electrospray ionization in an emitter needle (PicoTipTM, New Objective, 
Scientific Instrument Services, Ringoes, NJ, USA) with an applied voltage of 2,000V. 
Peptide masses (m/z 300-1700) were analyzed in data-dependent mode where a full 
scan MS was acquired on the Orbitrap with a resolution of 60,000 FWHM at 400m/z. 
Up to the 10 most abundant peptides (minimum intensity of 500 counts) were selected 
from each MS scan and then fragmented using CID (collision-induced dissociation) in 
the linear ion trap using helium as collision gas with 38% normalized collision energy. 
Multistage activation was enabled to favor the detection of phosphopeptides. The scan 




time settings were: full MS at 250ms and MSn at 120ms. Generated .raw data files 
were collected with Thermo Xcalibur (v.2.2) (Termo Fisher Scientific).  
Database search 
Thermo Proteome Discoverer (v. 2.0.0.802) was used to search the .raw data obtained 
in the MS analyses against a SwissProt/Uniprothuman database with the MASCOT 
search engine (v2.5). A target and decoy database was used in combination with the 
Percolator algorithm to assess the false discovery rate (FDR). The PhosphoRS node 
was used to provide a confidence measure for the localization of phosphorylation in the 
peptide sequences identified with this modification.  
Phosphopeptides analysis 
Before proceeding to the statistical analysis data were pre-processed in four sequential 
steps. (i) the phosphopeptide list was filtered in order to remove potential contaminants 
(i.e., residual peptides bound to the chromatographic column such as bovine serum 
proteins); (ii) phosphopeptides with the identical amino acid sequence as well as 
phosphosites were merged into a single phosphopeptide (i.e., methionine-oxidided and 
non-methionine oxidized phosphopeptides); (iii) the information on the multi-
phosphorylated peptides was split so that each phosphosite appears in a single row; 
and (iv) the final list of phosphosites was filtered to retain only the sites with a 
probability site value (pRS) greater than 75% (0.75). After that, missing not at random 
areas (MNAR) were imputed using the minimal area value detected in every run by the 
mass spectrometer. Missing values were considered MNAR when three valid values 
appear in one experimental condition and only one or no valid values appear in the 
other condition. 
Before the imputation step, the quantification values for every sample were log2-
normalized against the corresponding median. In order to avoid potential bias 
introduced by the phosphopeptide enrichment, this value is calculated, for every 
sample, using the intensity values of the total peptides. Finally, a two-sided t-test was 
performed for every phosphosite and the p-value adjusted by False Discovery Rate 
using the Benjamini-Hochberg procedure. 
Phosphomotif enrichment analysis 
The enrichment of potential phosphorylation motifs was performed usingthe motif-X 
web tool (http://motif-x.med.harvard.edu/) (50). Previous to the analysis, the 
phosphosites of interest were centered, using the canonical sequence for every protein 
in the human uniprot database, so that a final 15-mer was obtained for every 
phosphosite. The list of 15-mers was analysed at motif-x. The searching parameters 
used were “centered”, “foreground format,” and “width” or number of total characters in 
the motif (in our samples, “width”=15). The rest of the parameters were set by default. 




RNA purification, retrotranscription reaction and RT-qPCR for detection of 3R 
and 4R tau isoforms  
Purification of RNA from the temporal white matter in control, AD and ARTAG cases 
was carried out using RNeasy Lipid Tissue Mini Kit (Qiagen, Hilden, Germany) 
following the protocol provided by the manufacturer combined with DNase digestion to 
avoid extraction and later amplification of genomic DNA. The concentration of each 
sample was obtained from A260 measurements with NanoDrop 2000 
spectrophotometer (Thermo Scientific, Waltham, MA, USA). RNA integrity was tested 
using the Agilent 2100 BioAnalyzer (Agilent, Santa Clara, CA, USA). Retrotranscription 
reaction of RNA samples was carried out with the High-Capacity cDNA Archive kit 
(Applied Biosystems, Foster City, CA, USA) following the guidelines provided by the 
supplier, and using Gene Amp® 9700 PCR System thermocycler (Applied Biosystems). 
A parallel reaction for one RNA sample was processed in the absence of reverse 
transcriptase to rule out DNA contamination. Tau mRNA isoforms were assessed by 
using SYBR green quantitative RT-PCR; 1,000ng of total RNA was used as a template. 
cDNA samples obtained from the retrotranscription reaction were diluted 1:20 and 
duplicate SYBR green PCR assays for each gene were performed. For each reaction, 
2.5µl of cDNA was mixed with 1.25µl of forward primer 10μM, 1.25µl reverse primer 
10μM and 5µl of PowerUp™ SYBR® Green Master Mix (Applied Biosystems). The 
reactions were performed following the parameters: 50°C for 2 min, 95°C for 10 min, 
and 40 cycles at 95ºC for 15 sec and at 60°C for 1 min. SYBR green PCR data were 
captured using the Sequence Detection Software (SDS version 2.2, Applied 
Biosystems). Forward and reverse primer sequences for quantitative PCR were 3Rtau 
forward: GTCCGTACTCCACCCAAGTC; 3Rtau reverse: 
GTTTGTAGACTATTTGCACCTTC; 4Rtau forward:  
GGCGGGAAGATGCAGATAATTAAT; 4Rtau reverse:  
GTAGACTATTTGCACACTGCC. Parallel assays for each sample were carried out 
using primers for β-glucuronidase (GUS-β) forward: GTCTGCGGCATTTTGTCGG, 
reverse: CACACGATGGCATAGGAATGG; X-prolyl aminopeptidase P1 (XPNPEP1) 
forward: CTCATTCCTGTCAAGGAGAACC, reverse:  ACCACATGACGTTCCTCTCAG; 
and glyceraldehyde-3-phosphate dehydrogenase (GADPH) forward: 
CGCTCTCTGCTCCTCCTGTT and reverse: CCATGGTGTCTGAGCGATGT; as 
endogenous controls. For the data analysis, threshold cycle (CT) values for each 
sample were processed to obtain the double delta CT (ΔΔCT) values. First, delta CT 
(ΔCT) values were calculated as the normalized CT values of each target gene in 
relation to the CT of endogenous controls GUS-β, XPNPEP1 and GADPH. Then, 
ΔΔCT values were obtained from the ΔCT of each sample minus the mean ΔCT of the 




population of control samples. The fold change was calculated using the equation 2^(-
ΔΔCT). Mean fold-change values of each experimental group were analyzed by One 
Way ANOVA test with post-hoc Tukey by using GraphPad Prism version 5.01 (La Jolla, 
CA, USA) and Statgraphics Statistical Analysis and Data Visualization Software 
version.1 (Warrenton, VA, USA). 
Animals and tissue processing 
All animal procedures were carried out following the guidelines of the European 
Communities Council Directive 2010/63/EU and with the approval of the local ethical 
committee (University of Barcelona, Spain). 
Wild-type C57BL/6 mice were injected into the hippocampus at the coordinates AP: -
1.9, ML: ± 1.4 and DV: -1.5 for 10 min, followed by a waiting time of 5 min and removal 
of the needle 10 min later; or into the lateral ventricle at the coordinates AP: -0.6, ML: ± 
1.2 and DV: -2.2 for 15 min, followed by a waiting time of 4 min and removal of the 
needle 15 min later. The quantity injected was 0.8μL in every case. Each mouse was 
injected with inoculum from a single ARTAG (or AD) case. Animals were killed under 
anaesthesia at the desired time-periods and the brains were rapidly fixed with 
paraformaldehyde in phosphate buffer and embedded in paraffin. Consecutive serial 
sections 4μm thick were obtained with a sliding microtome; sections were stained with 
haematoxylin and eosin or processed for immunohistochemistry using the antibody 
AT8), 4Rtau and 3Rtau. Following incubation with the primary antibody, the sections 
were incubated with EnVision + system peroxidase for 30 min at room temperature. 
The peroxidase reaction was visualized with diaminobenzidine and H2O2. Control of the 
immunostaining included omission of the primary antibody; no signal was obtained 
following incubation with only the secondary antibody.  
Double-labeling immunofluorescence was carried out on de-waxed sections, 4μm thick, 
which were stained with a saturated solution of Sudan black B (Merck, DE) for 15 min 
to block autofluorescence of lipofuscin granules present in cell bodies, and then rinsed 
in 70% ethanol and washed in distilled water. The sections were boiled in citrate buffer 
to enhance antigenicity and blocked for 30 min at room temperature with 10% foetal 
bovine serum diluted in PBS. Then, the sections were incubated at 4ºC overnight with 
combinations of AT8 and one of the following primary antibodies: GFAP, Iba-1, Olig2 
and p38-P Thr180-Tyr182. Other sections were immunostained with anti-phospho 
tauThr181 and anti-NeuN (see Table I for the characteristics of the antibodies). After 
washing, the sections were incubated with Alexa488 or Alexa546 fluorescence 
secondary antibodies against the corresponding host species. Nuclei were stained with 
DRAQ5TM. After washing, the sections were mounted in Immuno-Fluore mounting 




medium, sealed, and dried overnight. Sections were examined with a Leica TCS-SL 
confocal microscope. 
  





TSAs were recognized using AT8 antibodies and 4Rtau immunoreactivity, but they 
were negative with anti-3Rtau antibodies. TSAs were localized in subpial and 
subependymal regions, perivascular areas, clusters in the temporal and frontal white 
matter, basal forebrain, caudate, amygdala (including white matter surrounding the 
amygdala), and medulla oblongata. The distribution of TSAs was subject to individual 
variations; its characteristics in every case are summarized in Table II.  
In agreement with our previous characterization of TSAs in AD (37), THAs in the 
present series were stained with specific tau antibodies against phospho-Thr181, 
phospho-Ser199, phospho-Thr231, phospho-Ser262, and phospho-Ser422, double-
phosphorylation sites phospho-Ser202-phospho-Thr205 (clone AT8) and phospho-
Ser396-404 (PHF1), conformational tau modifications at amino acids 5-15 (Alz50), and 
amino acids 312-322 (MC-1). TSAs were negative with antibodies against tau 
truncated at aspartic acid 421 (tau-C3). In addition, TSAs were stained with antibodies 
499 (recognizing amino acids 14-26), 229 (amino acids 229-233), and 394 (amino 
acids 394-398), and with antibody anti-tau-100 (phospho-Thr212/Ser214) (Figure 1 A-
L). Double-labeling immunofluorescence and confocal microscopy with antibody 499 
and specific tau antibody against phospho-Thr181, and with antibody 394 and anti-tau 
phospho-Thr181, disclosed 499 and 394 immunoreactivity in all TSAs (Figure 1 M, N).  
TSAs, as revealed with GFAP immunohistochemistry, showed small size and reduced 
numbers of branches in frontal white matter, temporal white matter, subpial region, and 
subependymal region (Figure 2). This was in contrast not only with astrocytes in 
control, younger individuals but especially with neighbouring reactive GFAP-
immunoreactive astrocytes in the same cases. Double-labeling immunofluorescence 
and confocal microscopy confirmed reduced GFAP immunoreactivity in TSAs (Figure 
3).  
YKL-40, used as a marker of inflammatory astrocytes (38), and vimentin was 
expressed in a subpopulation of astrocytes in control and ARTAG cases. The number 
of vimentin and YKL-40 positive astrocytes was higher in ARTAG when compared with 
controls in agreement with reactive astrogliosis (12). However, double-labelling 
immunofluorescence and confocal microscopy revealed reduced size and decreased 
number of immunoreactive processes in TSAs (Figure 4) 
Band pattern of tau in sarkosyl-insoluble fractions  
Dissected basal forebrain and medulla oblongata from ARTAG cases with abundant 
TSAs were processed in parallel with samples of the frontal cortex from AD cases 
stage V. Three phospho-tau bands (anti-tau phopho-Ser422) of 68kDa, 64kDa, and 
60kDa were seen in the frontal cortex of cases with AD. In addition, several bands of 




molecular weight between 50kDa and 30kDa together with a lower band of about 
23kDa, of variable intensity among cases, were found in AD. These corresponded to 
two bands of 4R tau between 68 and 60kDa, and several bands of lower molecular 
stained visualized with specific anti-4R antibodies, respectively. In contrast, the band 
pattern of ARTAG phospho-tau using the same antibody and processed in parallel with 
AD samples showed two bands of 68kDa and 64kDa, and several bands of lower 
molecular weight corresponding to truncated forms of tau. The lower phospho-tau band 
of about 23kDa was absent in ARTAG cases. Curiously, one sample of the medulla 
oblongata showed a very weak band of 68kDa and a weak double-band at 64 kDa. 
Parallel membranes blotted with 4Rtau antibodies showed a doublet of 64kDa (Figure 
5).  
3Rtau and 4Rtau ratios 
Although not significant, 3Rtau and 4Rtau mRNA expression levels were reduced in 
AD and ARTAG cases when compared with controls. The ratio 3Rtau/4Rtau was also 
reduced in AD and ARTAG cases when compared with controls. Yet no differences 
were seen between AD and ARTAG (Supplementary Figure 1)  
SOD2, AQP4 and GLT-1 immunoreactivity 
Single immunohistochemistry showed increased SOD2 immunoreactivity in subpial, 
subependymal, and some perivascular astrocytes, and in astrocytes of the white matter 
and basal forebrain in all cases with ARTAG when compared with middle-aged 
individuals. These findings were consistent with senescent modifications of astrocytes 
(18). Double-labeling immunofluorescence to SOD2 and phospho-tau clone AT8 
revealed that TSAs and non-TSAs in the same tissue section were immunoreactive to 
SOD2 (Figure 6A).  
AQP4 immunoreactivity was variable from one case to another, but in general terms it 
was more pronounced in the molecular layer, subependymal region, and basal 
forebrain in ARTAG in comparison with control samples. Individual variations did not 
permit a realistic quantitative validation in the present series. However, double-labeling 
immunofluorescence to AQP4 and tau AT8 in samples of the temporal white matter 
revealed AQP4 immunoreactivity at the cell membrane of TSAs. A similar pattern was 
seen in other glial cells in the temporal white matter with no phospho-tau deposition 
(Figure 6B). 
GLT-1 immunoreactivity was present in astrocytes of the basal forebrain, temporal 
white matter, subpial region at the level of the medulla oblongata, and subependymal 
regions (the regions here assessed) in control and ARTAG cases. Double-labeling 
immunofluorescence and confocal microscopy to GLT-1 and hyper-phosphorylated tau 




(clone AT8) identified GLT-1 immunoreactivity at the cell membrane of TSAs and non-
TSAs in the same tissue section in ARTAG (Figure 6C).   
Phosphoproteomics 
Phosphosites differences between control and ARTAG cases, as seen in the heat map 
in Figure 7A, were imputated as MNAR. One-hundred twenty-two phosphosites 
showed higher abundance in ARTAG when compared to controls, and thirty-six 
phosphosites were more abundant in controls when compared to ARTAG 
(Supplementary Table 1). Since some proteins showed various sites of phosphorylation 
the total number of differentially phosphorylated proteins was 109 and 31, respectively, 
for ARTAG and controls (Table III). Several phosphorylated proteins with identification 
of phosphorylation positions are shown in Table IV. Among them, GFAP was found to 
be phosphorylated at positions 8, 14, 82, and 424, and aquaporin 4 was 
phosphorylated at position 273. Interestingly, many neuronal and glial proteins were 
differentially phosphorylated in ARTAG. These include proteins of the cytoskeleton, 
kinases, proteins linked to calcium/calmodulin signalling, cAMP signalling and DNA 
repair, nuclear and nucleolar regulators, proteins linked to tight junctions, proteins 
linked to proteolysis, and synaptic proteins, among others (Table III). A smaller number 
of proteins showed decreased levels of phosphorylated peptides in ARTAG when 
compared with controls (Table III). Regarding microtubule associated proteins (MAPs), 
phosphorylation of MAP-tau (as expected), MAP1A, MAP1AA, MAPK1S and MAP2 
was greater in ARTAG, whereas phosphorylation of MAP1B, MAP4 and MAP6 was 
higher in controls.   
Phosphomotif-enriched analysis revealed a motif enriched in ARTAG (SP). This motif is 
a phosphorylation site used for a wide number of kinases such as MAPK (including 
p38) and CDKs (Figure 7B).  
Immunohistochemistry of selected phosphorylated proteins in ARTAG 
Double-labeling immunofluorescence revealed that TSAs co-localized GFAP-P, PKA-P, 
and p38-P. GFAP-P was expressed in hyper-phosphorylated tau-bearing and non-
hyper-phosphorylated tau-bearing astrocytes in the temporal white matter. TSAs co-
localized active forms (phosphorylated at specific sites) of kinases p38 and PKA α/β. 
Tuberin-P was expressed in neurons of the hippocampus but not in tau-containing 
astrocytes (Figure 8).  
Tau seeding in inoculated mice 
Mice injected with AD fractions showed phospho-tau deposits in the fimbria, corpus 
callosum, and neurons of the hippocampus seven months after inoculation. The 
distribution and profile in the two mice inoculated with homogenates from two different 
AD cases was the same as the pattern already described by others (18) thus validating 




those observations and serving as positive controls in the present series (data not 
shown).     
The first group of six ARTAG-treated mice were injected at the age of seven months, 
three in the ventricle and three in the hippocampus, and killed at the age of ten months. 
No tau deposits were seen following intraventricular injection. However, intracellular 
deposits of hyper-phosphorylated tau were found in threads and in a few cells in the 
fimbria, lateral corpus callosum, and lateral part of the hippocampus in two of the three 
mice injected in the hippocampus (Figure 9A and B). 
A second group of mice was injected into the hippocampus at the age of three months 
and killed at the age of ten months; four animals were inoculated with ARTAG and two 
with vehicle alone. All ARTAG-injected animals showed hyper-phosphorylated tau 
deposits in the fimbria, fornix, corpus callosum traversing the contralateral hemisphere, 
and the hippocampal complex including gyrus dentatus, CA1 and CA3 region of the 
hippocampus, and subiculum (Figure 9C-I). Curiously, cells were positive to 4Rtau 
(Figure 9J), as expected, but also to 3Rtau (Figure 9K and L). Double-labeling 
immunofluorescence and confocal microscopy disclosed hyper-phosphorylated tau 
deposition in neurons and astrocytes, as revealed with anti-NeuN and anti-GFAP 
antibodies, respectively, in animals with short interval between inoculation and 
examination (Figure 10A and B); microglia, as revealed with Iba-1 antibodies, did not 
contain hyper-phosphorylated tau (Figure 10C). Similar intracellular localization of 
hyper-phosphorylated tau was found in neurons and astrocytes in animals with long 
interval between inoculation and neuropathological examination, as revealed with the 
same antibodies; microglia did not contain hyper-phosphorylated tau deposits (Figure 
11A, C, D, E and F). In addition, hyper-phosphorylated tau was found in 
oligodendroglia mainly in corpus callosum as revealed by double-labeling 
immunofluorescence using anti-Olig2 antibodies (Figure 11G and H). Finally, the 
possibility that hyper-phosphorylated tau deposition was an active process within seeds 
was sustained by co-localization of active p38 kinase (phosphorylated at Thr180-
Tyr182) only in cells containing hyper-phosphorylated tau (Figure 11B). 
 
  






The morphological characteristics and distribution of TSAs in this ARTAG series with 
no tau deposition in neurons or with NFTs and pre-tangles restricted to the entorhinal 
and transentorhinal cortex are similar to those described in ARTAG associated with 
tauopathies (28, 29, 31, 36). The pattern of tau phosphorylation of TSAs identified here 
does not differ from TSAs associated with other tauopathies including AD and AGD 
(14, 37). Additional features of THAs include lack of evidence of truncated tau using 
specific antibodies against C-terminal and N-terminal regions, together with negativity 
to tau-C3 which recognizes truncated tau at Asp421. Gel electrophoresis and western 
blotting of sarkosyl-insoluble fractions show two bands of 68 kDa and 64 kDa (in some 
areas as a doublet) and several weaker bands of lower molecular weight. In no case 
are triple bands of 68kDa, 64kDa, and 60kDa and a lower band of truncated tau of 
about 20kDa, typical of AD, found in ARTAG. In conclusion, TSAs are composed of 
hyper-phosphorylated 4Rtau with features of pre-tangles lacking tau truncation at 
terminal regions.  
Considering that TSAs are present in aged brains, further analysis was carried out to 
learn about categorization of these astrocytes and functional implications of this 
particular astrocytopathy (12). TSAs show reduced GFAP expression, reduced volume, 
and reduced numbers of branches. This was further recognized using anti-vimentin and 
YKL-40 antibodies. SOD2 immunoreactivity, which is augmented in senescent 
astrocytes (48), is increased in TSAs when compared with astrocytes of younger 
individuals. Yet these features are not restricted to TSAs but also apply to neighboring 
astrocytes with no hyper-phosphorylated tau deposition. Moreover, neighboring 
astrocytes show increased area coverage, and increased GFAP, vimentin and YKL-40 
immunoreactivity. Therefore, TSAs are a subpopulation of astrocytes showing 
senescent features (18, 46, 48).  
Astrocytes have specific functions mediated by selective molecules and pathways, 
among them the modulation of glutamate transport through astroglial glutamate 
transporter solute carrier family 1, member 2 (GLT-1/ EAAT2) (39, 42). Double-labeling 
immunofluorescence and confocal microscopy identifies GLT-1 immunoreactivity at the 
cell membrane of TSAs and non-TSAs in the same tissue sections. Decreased GLT-1 
immunoreactivity in tau-containing astrocytes has been reported in a familial behavioral 
variant of frontotemporal dementia associated with astrocyte-predominant tauopathy, in 
which astrocytes show advanced stage of tangle formation with tau truncation and 
ubiquitination (13). GLT-1 expression is also altered in transgenic mice with astroglial 
tau phosphorylation (10); tau in transgenic mice is abnormally phosphorylated, 




ubiquitinated, and filamentous; abnormal astrocytes are variably positive with 
thioflavine S (17). Therefore, relative preservation of GLT-1 in TSAs compared with 
astrocytes in the previous conditions may be related to the less advanced stage of 
cellular damage linked to tau phosphorylation and truncation in ARTAG.    
Another important function of astrocytes is the regulation of water homeostasis through 
specific water channel aquaporin 4. AQP4 is expressed at the cell membrane of 
astrocytes, particularly at the perivascular, subpial, and subependymal interfaces (2).  
Double-labeling immunofluorescence to AQP4 and tau AT8 in samples of the temporal 
white matter shows AQP4 immunoreactivity in TSAs and in other astrocytes. Due to 
individual variations we are not able to conclude that AQP4 immunoreactivity is 
specifically altered in TSAs. However, this does not dismiss the possibility of blood-
brain barrier dysfunction in ARTAG as suggested in other studies (33, 35). 
The study of the phosphoproteome in relatively pure cases of ARTAG, although limited 
by the small number of cases, avoids possible contamination of altered tau in ARTAG 
associated with other tauopathies. Several proteins in ARTAG have differential 
phosphorylation marks when compared with controls, among them AQP4 at Thr273 
and GFAP at positions 8, 14, 82, and 424. GFAP phosphorylation at Ser8 was further 
validated by immunohistochemistry and immunofluorescence and characterized by 
confocal microscopy. GFAP is phosphorylated at different sites of the amino-terminal, 
thus modulating filaments assembly (24, 43, 52). Several kinases phosphorylate GFAP 
at specific sites; Cdc2 kinase (cyclin dependent kinase 1) phosphorylates GFAP at 
Ser8 whereas Ca(2+)-CaM-dependent protein kinase II phosphorylates GFAP at  
Ser13, Ser17, Ser34, and Ser389 (56). The role of cAMP-dependent and Ca2+-
dependent protein kinases on GFAP phosphorylation has also been studied in 
digitonin-permeabilized astrocytes exposed to cAMP and Ca2+ which increases the 
phosphorylation state of GFAP (25). Despite these achievements, little is known about 
the effect of combined phosphorylation at different sites on GFAP filament assembly 
(52).  
Phosphorylation of some aquaporins has been proposed as regulating their water 
permeability via gating of the channel itself. Certain protein kinases phosphorylate 
AQP4 thus facilitating AQP4 trafficking and water permeability (20, 26). However, 
studies in Xenopus oocytes have shown that phosphorylation at COOH-terminal 
residues Ser180, Ser276, Ser285, Ser315, Ser316, Ser321, and Ser322 does not 
modulate trafficking or channel gating (1, 3, 47). Thus, regulatory patterns and 
physiological roles for AQP4 remain to be fully explored (2); functional studies are 
needed to learn about the functional role of AQP4 phosphorylation at Thr273 and its 
implication in ARTAG. 




Phosphoproteomics has also evidenced increased phosphorylation marks in several 
kinases including calcium/calmodulin-dependent protein kinase type II subunit gamma, 
cAMP-dependent protein kinase catalytic subunit alpha, c-Jun-amino-terminal kinase-
interacting protein 3, cyclin-dependent kinase 12, protein kinase C alpha type, and 
protein kinase C epsilon type. Since a typical protein kinase must distinguish one from 
among a few hundred bona fide phosphorylation sites in a background of 
approximately 700,000 potentially phosphorylatable residues (57), it is premature to 
advance which are the substrates of such activated kinases in the context of ARTAG. 
In spite of the large number of putative targets, double-labeling immunofluorescence 
has shown co-localization of active kinases p38 and PKA α/β with hyper-
phosphorylated tau in TSAs in ARTAG. Moreover, many other proteins are 
phosphorylated at specific sites in ARTAG including MAP7 domain-containing protein 
1, microtubule-associated protein 1A, microtubule-associated protein 1AA, microtubule-
associated protein 1B, microtubule-associated protein 1S, and microtubule-associated 
protein 2, in addition to microtubule-associated protein tau. Furthermore, increased 
phosphorylation of microtubule-associated protein 1B, microtubule-associated protein 
4, and microtubule-associated protein 6 is found in controls compared with ARTAG. 
Several neuronal proteins, such as synaptic proteins synapsin-1, synaptophysin, 
synaptopodin and synaptophilin; and tuberin, are also differentially phosphorylated in 
ARTAG, indicating that differences in the phosphorylation state of various cytoskeletal 
and non-cytoskeletal proteins are not limited to astrocytes but also compromise 
neurons. Little is known about functional implications of tuberin phosphorylation. 
However, since tuberin is linked to microtubule biology through ROCK2 signaling (15), 
it can be suggested that changes in tuberin phosphorylation modify microtubule 
organization.   
Several studies in AD have located differentially phosphorylated proteins in the 
cerebral cortex and hippocampus using bi-dimensional gel electrophoresis and mass 
spectrometry. Most proteins are linked to energy metabolism, neuronal plasticity, signal 
transduction, and oxidative stress responses (11, 55, 59). These studies also identify 
GFAP as a phosphorylated protein in AD. More recently, phosphopeptide enrichment 
and LC-MS/MS assessment have identified more than one thousand phosphorylated 
proteins in AD (53). In another study, most of the core phosphoproteins are directly 
connected and form a functional network linked to synaptic spine formation. Systems 
biology analyses suggest that over-activated kinases including protein kinases C and 
calmodulin-dependent kinases initiate synapse pathology (51). The change of the core 
network starts at a preclinical stage even before histological β-amyloid deposition (51). 




The study of Tagawa et al. (51) points to similarities between AD and ARTAG 
regarding phosphorylation of similar kinases and synaptic proteins. These 
modifications in AD are independent of β-amyloid and phosphor-tau deposition, and in 
ARTAG cases independent of neurofibrillary tangle pathology as well. In addition, 
GFAP phosphorylation is not restricted to ARTAG but also occurs in AD.  
The present observations suggest that TSAs are just part of the modifications occurring 
in ARTAG. TSAs are developed in selected populations of senescent astrocytes in a 
context of increased protein phosphorylation among which are several kinases with the 
capacity to phosphorylate a large number of substrates. These observations in several 
regions not associated with neuronal tau pathology in ARTAG identify changes which 
are common to AD, and they may explain the frequency of ARTAG in AD and other 
tauopathies in the elderly.  
Finally, the present study shows for the first time the capacity of tau seeding of 
sarkosyl-insoluble fractions enriched in hyper-phosphorylated tau from selected 
ARTAG cases in which TSAs are the only source of abnormal hyperphosphorylated 
tau. Therefore, certain subpopulations of astrocytes may be primary carriers for 
abnormal tau seeding. Moreover, tau seeding in our model occurred not only in host 
astrocytes but also in neurons and oligodendroglia, thus pointing out that neurons and 
oligodendrocytes can be seed targets of astrocyte-derived hyper-phosphorylated tau. 
This is important, as hyper-phosphorylated tau inclusions are frequent in 
oligodendrocytes in AGD and in other tauopathies (16, 27). Present observations 
support the hypothesis that TSAs may facilitate tau hyper-phosphorylation and 
deposition in neurons and other glial cells in human tauopathies, and they point to the 
cardinal role of astrocytopathy in the pathogenesis of neurodegenerative diseases with 
abnormal protein aggregates. The morphology of tau-containing astrocytes after 
ARTAG inoculation in mice does not have the morphology of TSAs. Its distribution and 
that of tau-containing neurons and oligodendrocytes in ARTAG-inoculated mice 
correlate with the inoculation site rather than with the distribution of TSAs in ARTAG. In 
fact, the same pattern is seen following the inoculation of AD homogenates, in 
agreement with previous observations with AD extracts (19).Therefore, additional 
factors must be examined in the future mainly those related with the age of the 
inoculated animals. ARTAG is a tauopathy related to aging and TSAs are senescent 
astrocytes. Inoculation of ARTAG (and AD) homogenates in old animals is mandatory 
to move closer to the environment occurring in old age.        
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Figure 1: A-L: single immunohistochemistry with anti-tau antibodies directed to N-
terminal, middle, and C-terminal regions of tau. A, D, G, J: subependymal astrocytes; 
B, E, H, K: subpial astrocytes; C, F, I, L: temporal white matter. A-C: antibody 499 
(amino acids 14-26; amino terminal); D-F: antibody 229 (amino acids 229-233, middle 
regioin); G-I: antibody 394 (amino acids 394-398, C-terminal ); J-L: antibody tau-100 
(P-tau Thr212-Ser214). TSAs are stained with all these antibodies. Paraffin sections 
slightly counterstained with haematoxylin; A-I, bar in I = 25μm; J-L, bar in L = 100μm. 
M, N: double-labeling immunofluorescence and confocal microscopy using (M) 
antibody 499 (green) and P-tau Thr181 (red); and (N) antibody 394 (green) and P-tau 
Thr181 (red) in the vicinity of a blood vessel (M, asterisk) and in the temporal white 
matter. N-terminal and C-terminal tau segments are co-expressed with phosphorylated 
tau. Paraffin sections; nuclei (blue) are stained with DRAQ5TM; M, bar = 75μm; N, bar = 
40μm. 
 
Figure 2: GFAP-immunoreactive astrocytes in white matter (A-D) (A) and ARTAG 
cases in TSAs-rich regions (B) and neighboring regions without TSAs astrocytes (C). 
GFAP-positive astrocytes in ARTAG regions without TSAs have larger branches when 
compared with controls. However, THAs have smaller size and reduced number of 
branches when compared with astrocytes in controls. Paraffin sections; nuclei (blue) 
are stained with DRAQ5 TM; bar = 50μm. Particle selection mascara of astrocytes is 
shown in white matter (D). Quantification of astrocytes areas per μm2 (left lower 
panels) and astrocyte average size (right lower panels). Graphs show mean ± SEM of 
three different sections. Quantifications analyzed by One-way ANOVA show significant 
difference among groups *p<0.05 in white matter astrocyte coverage area; Turkey 
post-hoc shows significant differences #p<0.05 in astrocyte coverage area between 
THAs (P-tau+) and neighboring P-tau negative (P-tau-) astrocytes in ARTAG. 
 
Figure 3: Double-labeling immunofluorescence to GFAP (green) and AT8 (red) 
showing the morphology of TSAs in the temporal white matter. Short arrow: cells only 
stained green; arrowhead: cells only stained red. Hyper-phosphorylated tau-containing 
astrocytes have reduced GFAP immunoreactivity.  Paraffin sections; nuclei (blue) are 
stained with DRAQ5TM; bar = 50μm.  
 
Figure 4: A: Double-labeling immunofluorescence to YKL-40 (green) and AT8 (red) in 
one cluster of TSAs in temporal white matter. B: Double-labeling immunofluorescence 




to vimentin (green) and AT8 (red) in temporal white matter. Note decreased YKL-40 
and vimentin immunoreactivy in TSAs. Long arrow: cells with double staining; short 
arrow: cells only stained green; arrowhead: cells only stained red. Paraffin sections, 
nuclei stained with DRAQ5TM (blue); bar = 50μm.  
 
Figure 5: Gel electrophoresis and western blotting of sarkosyl-insoluble fractions from 
frontal cortex of Alzheimer disease stage V (ADV) processed in parallel with ARTAG; 
upper panel, basal forebrain; lower panel medulla oblongata.  Three phospho-tau 
bands (antibody P-tau Ser422) of 68kDa, 64kDa, and 60kDa; several bands of 
molecular weight between 50kDa and 30kDa, and a lower band of about 23kDa are 
seen in AD. These correspond to two bands of 4R tau between 68 and 60kDa and 
several bands of lower molecular stained visualized with specific anti-4R antibodies. In 
contrast, two bands of 68kDa and 64kDa, and several bands of lower molecular weight 
corresponding to truncated forms of tau are seen in ARTAG. The lower phospho-tau 
band of about 23kDa is absent in ARTAG. Curiously, a very weak band of 68kDa and a 
weak double-band at 64 kDa are seen in medulla oblongata. Parallel membranes 
blotted with 4Rtau antibodies show a doublet of 64 kDa.  
  
Figure 6: Double-labeling immunofluorescence to SOD2 (green) and hyper-
phosphorylated tau (clone AT8: red) (A), AQP4 (green), and tau AT8 (red) (B) in the 
temporal white matter, and GLT-1 (green) and hyper-phosphorylated tau (clone AT8: 
red) in the subpial region at the level of the medulla oblongata (C). TSAs and non-
TSAs are equally immunoreactive to SOD2. TSAs, like other astrocytes in the temporal 
white matter, exhibit low AQP4 immunoreactivity which is displaced to the periphery by 
tau deposits. TSAs have GLT-1 immunoreactivity at the cell membrane. Long arrow: 
cells with double staining; short arrow: cells only stained green; arrowhead: cells only 
stained red. Paraffin sections, nuclei (blue) are stained with DRAQ5TM, A-F, bar = 
40μm; G-I, bar = 10μm.  
 
Figure 7: A: Heat map of phosphosites in control (CC) and ARTAG (AG) cases 
showing differences between the two groups. B: Phosphomotif enrichment analysis 
reveals the motif SP enriched in the ARTAG samples. The SP site is a phosphorylation 
site used for a wide number of kinases such as MAPKs (including p38) and CDKs. 
 
Figure 8: Double-labeling immunofluorescence with antibodies against GFAP-P and 
tau Thr181 (A), anti-PKA-P (B), anti-p38-P (C), and anti-tuberin-P (D) and AT8 in 
ARTAG. TSAs contain GFAP-P, PKA-P, and p38-P but not tuberin-P. GFAP-P is 




expressed in hyper-phosphorylated tau-bearing and non-hyper-phosphorylated tau-
bearing astrocytes in the temporal white matter. Tuberin-P is expressed in neurons of 
the hippocampus but not in tau-containing astrocytes. Long arrow: cells with double 
staining; short arrow: cells only stained green; arrowhead: cells only stained red. 
Paraffin sections; nuclei (blue) are stained with DRAQ5TM; bar = 40μm.  
Figure 9: Hyper-phosphorylated tau containing cells following intra-hippocampal 
inoculation of sarkosyl-insoluble fractions from ARTAG cases to WT mice. A, B: 
inoculated at 7 months and killed at the age of 10 months; C-L: inoculated at 3 months 
and killed at the age of 10 months. A, C: fimbria; B: hippocampus; D-F, I: corpus 
callosum; J, K: CA1 region of the hippocampus; H: subiculum; G-L: dentate gyrus. A-I: 
antibody tau AT8; J: anti-4Rtau; K, L: anti-3Rtau. Paraffin sections slightly 
counterstained with haematoxylin; A-L, excepting D, bar in L = 25μm; D, bar = 100μm.  
 
Figure 10: WT mice inoculated with ARTAG in the hippocampus at the age of 7 
months and killed at the age of 10 months. A: Double-labeling immunofluorescence  to 
NeuN (green) and P-tau Thr181 (red). B: Double-labeling immunofluorescence to 
GFAP (green) and AT8 (red). C: Double-labeling immunofluorescence to Iba-1 (green) 
and AT8 (red). Subpopulations of neurons and astrocytes, but not microglia, contain 
hyper-phosphorylated tau. Paraffin sections, nuclei stained with DRAQ5TM (blue). Long 
arrow: cells with double staining; short arrow: cells only stained green; arrowhead: cells 
only stained red. A, bar = 30μm; B, bar = 20μm; C, bar = 50μm. 
 
Figure 11: WT mice inoculated with ARTAG in the hippocampus at the age of 3 
months and killed at the age of 10 months. A: Double-labeling immunofluorescence to 
NeuN (green) and tauThr181 (red). B: Double-labeling immunofluorescence to 
phosphorylated p38 Thr180-Tyr182 (green) and AT8 (red). C, D: Double-labeling 
immunofluorescence to GFAP (green) and AT8 (red). E, F: Double-labeling 
immunofluorescence to Iba-1 (green) and AT8 (red). G, H: Double-labeling 
immunofluorescence to Olig2 (green) and AT8 (red). Subpopulations of neurons (A, B), 
astrocytes (C, D) and oligodendrocytes (G, H) contain hyper-phosphorylated tau. 
Hippocampal neurons containing hyper-phosphorylated tau co-express active tau 
kinase p38. Long arrow: cells with double staining; short arrow: cells only stained 
green; arrowhead: cells only stained red. Paraffin sections, nuclei stained with 
DRAQ5TM (blue); bar = 25μm. 
  





Supplementary Figure 1: mRNA expression levels of 3R tau and 4R tau in the 
temporal white matter in middle-aged (MA) control cases, Alzheimer’s disease (AD) 
and ARTAG cases (A), and 3Rtau/4Rtau mRNA ration in every group (B). No 
significant differences are observed at mRNA level, but a tendency to decreased 3Rtau 










Figure 1: A-L: single immunohistochemistry with anti-tau antibodies directed to N-terminal, middle, and C-
terminal regions of tau. A, D, G, J: subependymal astrocytes; B, E, H, K: subpial astrocytes; C, F, I, L: 
temporal white matter. A-C: antibody 499 (amino acids 14-26; amino terminal); D-F: antibody 229 (amino 
acids 229-233, middle regioin); G-I: antibody 394 (amino acids 394-398, C-terminal ); J-L: antibody tau-
100 (P-tau Thr212-Ser214). TSAs are stained with all these antibodies. Paraffin sections slightly 
counterstained with haematoxylin; A-I, bar in I = 25µm; J-L, bar in L = 100µm. M, N: double-labeling 
immunofluorescence and confocal microscopy using (M) antibody 499 (green) and P-tau Thr181 (red); and 
(N) antibody 394 (green) and P-tau Thr181 (red) in the vicinity of a blood vessel (M, asterisk) and in the 
temporal white matter. N-terminal and C-terminal tau segments are co-expressed with phosphorylated tau. 
Paraffin sections; nuclei (blue) are stained with DRAQ5TM; M, bar = 75µm; N, bar = 40µm.  
 




Figure 2: GFAP-immunoreactive astrocytes in white matter (A-D) (A) and ARTAG cases in TSAs-rich regions 
(B) and neighboring regions without TSAs astrocytes (C). GFAP-positive astrocytes in ARTAG regions without 
TSAs have larger branches when compared with controls. However, THAs have smaller size and reduced 
number of branches when compared with astrocytes in controls. Paraffin sections; nuclei (blue) are stained 
with DRAQ5 TM; bar = 50µm. Particle selection mascara of astrocytes is shown in white matter (D). 
Quantification of astrocytes areas per µm2 (left lower panels) and astrocyte average size (right lower 
panels). Graphs show mean ± SEM of three different sections. Quantifications analyzed by One-way ANOVA 
show significant difference among groups *p<0.05 in white matter astrocyte coverage area; Turkey post-
hoc shows significant differences #p<0.05 in astrocyte coverage area between THAs (P-tau+) and 








Figure 3: Double-labeling immunofluorescence to GFAP (green) and AT8 (red) showing the morphology of 
TSAs in the temporal white matter. Short arrow: cells only stained green; arrowhead: cells only stained red. 
Hyper-phosphorylated tau-containing astrocytes have reduced GFAP immunoreactivity.  Paraffin sections; 
nuclei (blue) are stained with DRAQ5TM; bar = 50µm.  
 




Figure 4: A: Double-labeling immunofluorescence to YKL-40 (green) and AT8 (red) in one cluster of TSAs in 
temporal white matter. B: Double-labeling immunofluorescence to vimentin (green) and AT8 (red) in 
temporal white matter. Note decreased YKL-40 and vimentin immunoreactivy in TSAs. Long arrow: cells 
with double staining; short arrow: cells only stained green; arrowhead: cells only stained red. Paraffin 
sections, nuclei stained with DRAQ5TM (blue); bar = 50µm.  
 




Figure 5: Gel electrophoresis and western blotting of sarkosyl-insoluble fractions from frontal cortex of 
Alzheimer disease stage V (ADV) processed in parallel with ARTAG; upper panel, basal forebrain; lower 
panel medulla oblongata.  Three phospho-tau bands (antibody P-tau Ser422) of 68kDa, 64kDa, and 60kDa; 
several bands of molecular weight between 50kDa and 30kDa, and a lower band of about 23kDa are seen in 
AD. These correspond to two bands of 4R tau between 68 and 60kDa and several bands of lower molecular 
stained visualized with specific anti-4R antibodies. In contrast, two bands of 68kDa and 64kDa, and several 
bands of lower molecular weight corresponding to truncated forms of tau are seen in ARTAG. The lower 
phospho-tau band of about 23kDa is absent in ARTAG. Curiously, a very weak band of 68kDa and a weak 
double-band at 64 kDa are seen in medulla oblongata. Parallel membranes blotted with 4Rtau antibodies 
show a doublet of 64 kDa.  
 




Figure 6: Double-labeling immunofluorescence to SOD2 (green) and hyper-phosphorylated tau (clone AT8: 
red) (A), AQP4 (green), and tau AT8 (red) (B) in the temporal white matter, and GLT-1 (green) and hyper-
phosphorylated tau (clone AT8: red) in the subpial region at the level of the medulla oblongata (C). TSAs 
and non-TSAs are equally immunoreactive to SOD2. TSAs, like other astrocytes in the temporal white 
matter, exhibit low AQP4 immunoreactivity which is displaced to the periphery by tau deposits. TSAs have 
GLT-1 immunoreactivity at the cell membrane. Long arrow: cells with double staining; short arrow: cells 
only stained green; arrowhead: cells only stained red. Paraffin sections, nuclei (blue) are stained with 
DRAQ5TM, A-F, bar = 40µm; G-I, bar = 10µm.  
 




Figure 7: A: Heat map of phosphosites in control (CC) and ARTAG (AG) cases showing differences between 
the two groups. B: Phosphomotif enrichment analysis reveals the motif SP enriched in the ARTAG samples. 
The SP site is a phosphorylation site used for a wide number of kinases such as MAPKs (including p38) and 
CDKs.  
 




Figure 8: Double-labeling immunofluorescence with antibodies against GFAP-P and tau Thr181 (A), anti-
PKA-P (B), anti-p38-P (C), and anti-tuberin-P (D) and AT8 in ARTAG. TSAs contain GFAP-P, PKA-P, and p38-
P but not tuberin-P. GFAP-P is expressed in hyper-phosphorylated tau-bearing and non-hyper-
phosphorylated tau-bearing astrocytes in the temporal white matter. Tuberin-P is expressed in neurons of 
the hippocampus but not in tau-containing astrocytes. Long arrow: cells with double staining; short arrow: 
cells only stained green; arrowhead: cells only stained red. Paraffin sections; nuclei (blue) are stained with 
DRAQ5TM; bar = 40µm.  
 




Figure 9: Hyper-phosphorylated tau containing cells following intra-hippocampal inoculation of sarkosyl-
insoluble fractions from ARTAG cases to WT mice. A, B: inoculated at 7 months and killed at the age of 10 
months; C-L: inoculated at 3 months and killed at the age of 10 months. A, C: fimbria; B: hippocampus; D-
F, I: corpus callosum; J, K: CA1 region of the hippocampus; H: subiculum; G-L: dentate gyrus. A-I: 
antibody tau AT8; J: anti-4Rtau; K, L: anti-3Rtau. Paraffin sections slightly counterstained with 
haematoxylin; A-L, excepting D, bar in L = 25µm; D, bar = 100µm.  
Figure 9: Hyper-phosphorylated tau containing cells following intra-hippocampal inoculation of sarkosyl-
insoluble fractions from ARTAG cases to WT mice. A, B: inoculated at 7 months and killed at the age of 10 
months; C-L: inoculated at 3 months and killed at the age of 10 months. A, C: fimbria; B: hippocampus; D-
F, I: corpus callosum; J, K: CA1 region of the hippocampus; H: subiculum; G-L: dentate gyrus. A-I: 
antibody tau AT8; J: anti-4Rtau; K, L: anti-3Rtau. Paraffin sections slightly counterstained with 
haematoxylin; A-L, excepting D, bar in L = 25µm; D, bar = 100µm.  
 




Figure 10: WT mice inoculated with ARTAG in the hippocampus at the age of 7 months and killed at the age 
of 10 months. A: Double-labeling immunofluorescence  to NeuN (green) and P-tau Thr181 (red). B: Double-
labeling immunofluorescence to GFAP (green) and AT8 (red). C: Double-labeling immunofluorescence to 
Iba-1 (green) and AT8 (red). Subpopulations of neurons and astrocytes, but not microglia, contain hyper-
phosphorylated tau. Paraffin sections, nuclei stained with DRAQ5TM (blue). Long arrow: cells with double 
staining; short arrow: cells only stained green; arrowhead: cells only stained red. A, bar = 30µm; B, bar = 
20µm; C, bar = 50µm.  
 




Figure 11: WT mice inoculated with ARTAG in the hippocampus at the age of 3 months and killed at the age 
of 10 months. A: Double-labeling immunofluorescence to NeuN (green) and tauThr181 (red). B: Double-
labeling immunofluorescence to phosphorylated p38 Thr180-Tyr182 (green) and AT8 (red). C, D: Double-
labeling immunofluorescence to GFAP (green) and AT8 (red). E, F: Double-labeling immunofluorescence to 
Iba-1 (green) and AT8 (red). G, H: Double-labeling immunofluorescence to Olig2 (green) and AT8 (red). 
Subpopulations of neurons (A, B), astrocytes (C, D) and oligodendrocytes (G, H) contain hyper-
phosphorylated tau. Hippocampal neurons containing hyper-phosphorylated tau co-express active tau kinase 
p38. Long arrow: cells with double staining; short arrow: cells only stained green; arrowhead: cells only 
stained red. Paraffin sections, nuclei stained with DRAQ5TM (blue); bar = 25µm.  
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Dilution Supplier  Country 
β-amyloid monoclonal 1:50 Dako Glostrup, DK 
Aβ-40 rabbit 
polyclonal 
1:100 Merck-Millipore Billerica, MA, USA 
Aβ-42 rabbit 
polyclonal 





Billerica, MA, USA 
TDP-43 rabbit 
polyclonal 
1:200 Abcam Cambridge, UK 
p62C guinea pig 
polyclonal 
1:100 Progen, RA 
Biopharm 
Darmstadt, GE 
p62N guinea pig 
polyclonal 





1:1000 Wako Richmond, VA, USA 
4Rtau monoclonal 1:50 Merck-Millipore Billerica, MA,USA 
3Rtau monoclonal 1:800 Merck-Millipore Billerica, MA, USA 
phospho-tau Thr181 rabbit 
polyclonal 
1:50 Cell Signaling Danvers, MA,USA 
phospho-tau Ser199 rabbit 
polyclonal 
1:50 Calbiochem Darmstadt, GE 
phospho tau Thr231 rabbit 
polyclonal 
1:50 Calbiochem Darmstadt, GE 
phospho-tau Ser262 rabbit 
polyclonal 
1:50 Calbiochem Darmstadt, GE 
phospho-tau Ser422 rabbit 
polyclonal 
1:50 Calbiochem Darmstadt, GE 
AT8 (Ser202/Thr205) monoclonal 1:50 Innogenetics Ghent, BE 
Tau-100 
(Thr212/Ser214) 
monoclonal 1:100 Thermo 
Scientific 
Waltham, MA, USA 
PHF1(Ser396/Ser404) monoclonal 1:500 Dr. Peter Davies New York, USA 
Alz50 (aa 5-15) monoclonal 1:20 Dr. Peter Davies New York, USA 
MC-1 (aa312-322) monoclonal 1:50 Dr. Peter Davies USA 
tau-C3 (tr Asp421) monoclonal 1:300 Abcam  Cambridge, UK 
Ab 499 (aa 14-26) monoclonal  1:20 Dr. Jose Luna CDMX, Mexico DF 
Ab 229 (aa 229-233) rabbit 
polyclonal 
1:100 Dr. Jose Luna CDMX, Mexico DF 
Ab 394 (aa 394-398) rabbit 
polyclonal 
1:100 Dr. Jose Luna CDMX, Mexico DF 
ubiquitin rabbit 
polyclonal 
1:200 Dako Glostrup, DK 




1:500 Dako Glostrup, DK 
SOD2 rabbit 
polyclonal 
1:100 Stressgen San Diego, CA, USA 
AQP4 monoclonal 1:400 Sigma St Louis, Missouri, 
USA 
GLT-1 guinea pig 1:100 Merck-Millipore Billerica, MA,USA 
P-GFAP Ser8 Rabbit 
polyclonal 
1:500 Abcam  Cambridge, UK 
P-tuberin Ser939 Rabbit 
polyclonal 
1:100 Cell Signaling Danvers, MA,USA 
P-PKA α-β Thr197 Rabbit 1:100 Invitrogen Carlsbad, CA, USA 
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polyclonal 
P38-P Thr180-Tyr182 rabbit 
polyclonal 
1:100 Cell Signaling Danvers, MA, USA 
vimentin rabbit 
polyclonal 
1:400 Abcam  Cambridge, UK 
YKL-40 rabbit 
polyclonal 
1:200 Invitogen Carlsbad, CA, USA 
Olig-2 rabbit 
polyclonal  
1:500 Abcam  Cambridge, UK 
NeuN mouse 
monoclonal 
1:100 Merck-Millipore Billerica, MA,USA 
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Table II: Summary of ARTAG cases 
THAs: thorn-shaped astrocytes; subepend: subependymal; subpial: subpial; WM T: clusters in the temporal white matter; WM F: clusters in the 
frontal white matter; perivasc: perivascular; bas foreb: basal forebrain; caudate: caudate nucleus; med obl: medulla oblongata; PART: Primary 
age-related tauopathy (Braak and Braak staging of NFT pathology); LBD: Lewy body disease; AGD: argyrophilic grain disease.    
 
 
Case Age Gender Pm delay                                                                  THAs                                    other 
 subepend subpial WM  T WM  F perivasc bas foreb caudate amygdala med obl  
1 66 M 8 + + + - + + - + - PART0 
2 78 F 4 ++ + ++ + + + + ++ ++ PARTI 
3 87 F 18 ++ ++ ++ + ++ ++ + + ++ PARTI 
4 68 M 12 + ++ ++ + + + + + - PART I 
5 75 M 5h 30 m ++ ++ ++ ++ + ++ + ++ + PARTII 
6 86 M 16 ++ ++ ++ + + + - + - PARTI 
7 70 M 17 ++ + ++ + ++ + + + - LBD3 
8 86 M 12 ++ ++ ++ + ++ ++ + + + AGDI 
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Table III: List of proteins differentially up-phosphorylated in ARTAG when compared 
with controls (A) and list of proteins differentially up-phosphorylated in controls when 
compared with ARTAG (B). See Supplementary Table 1 for details of phosphosites.  
(A) 




Abl interactor 1 Q8IZP0 S222 
Adenylate cyclase type 6 O43306 S54 
Amyloid beta A4 protein P05067 S441 
Ankyrin-2 Q01484 S2405 
Ankyrin-3 Q12955 S623/T1443/S3055 
AP2-associated protein kinase 1 Q2M2I8 S938 
Aquaporin-4 P55087 T273 
Arf-GAP with SH3 domain, ANK repeat and PH domain-
containing protein 1 
Q9ULH1 S1008 
ATP-dependent 6-phosphofructokinase, platelet type Q01813 T313 
B-cell lymphoma/leukemia 11A Q9H165 S608 
Beta-2-syntrophin Q13425 S95 
Brefeldin A-inhibited guanine nucleotide-exchange 
protein 1 
Q9Y6D6 S1079 
Brefeldin A-inhibited guanine nucleotide-exchange 
protein 2 
Q9Y6D5 S277 
C-Jun-amino-terminal kinase-interacting protein 3 Q9UPT6 T275 
C-type mannose receptor 2 Q9UBG0 S1457 
Calcium-binding and coiled-coil domain-containing 
protein 1 
Q9P1Z2 S563 
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide 
phosphodiesterase 1C 
Q14123 S469 
Calcium/calmodulin-dependent protein kinase type II 
subunit gamma 
Q13555 S276 
Calmodulin-regulated spectrin-associated protein 3 Q9P1Y5 S553 
cAMP-dependent protein kinase catalytic subunit alpha P17612 T198/S339 
cAMP-regulated phosphoprotein 19 P56211 S104 
cAMP-specific 3',5'-cyclic phosphodiesterase 4B Q07343 S290 
CAP-Gly domain-containing linker protein 3 Q96DZ5 S402 
Capping protein, Arp2/3 and myosin-I linker protein 2 Q6F5E8 S991 
Catenin beta-1 P35222 S552/S675 
Catenin delta-2 Q9UQB3 S201/S285 
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Centriole, cilia and spindle-associated protein Q6IQ19 S240 
Clathrin coat assembly protein AP180 O60641 S296 
Clathrin interactor 1 Q14677 S227/S299 
Creatine kinase B-type P12277 T322 
Creatine kinase U-type, mitochondrial P12532 S318 
Cyclin-dependent kinase 12 Q9NYV4 S1082 
Cysteine-rich protein 2 P52943 S114 
Dematin Q08495 S11 
Dendrin O94850 S567 
DENN domain-containing protein 4B O75064 S736 
Dihydropyrimidinase-related protein 1 Q14194 T509 
Disks large-associated protein 1 O14490 S397 
DNA repair protein XRCC1 P18887 S241 
E3 ubiquitin-protein ligase UBR4 Q5T4S7 T2724 
FERM, RhoGEF and pleckstrin domain-containing 
protein 1 
Q9Y4F1 S427 
Glial fibrillary acidic protein P14136 S8/Y14/S82/S424 
Glutamate receptor-interacting protein 1 Q9Y3R0 S953 
Glycylpeptide N-tetradecanoyltransferase 2 O60551 S68 
Growth arrest-specific protein 7 O60861 S163 
Guanine nucleotide-binding protein G(I)/G(S)/G(O) 
subunit gamma-12 
Q9UBI6 S7 
IQ motif and SEC7 domain-containing protein 1 Q6DN90 S105 
Junctional protein associated with coronary artery 
disease 
Q9P266 S757 
Kinase suppressor of Ras 2 Q6VAB6 S474 
LIM and calponin homology domains-containing protein 
1 
Q9UPQ0 S670 
Liprin-alpha-2 O75334 S774 
LysM and putative peptidoglycan-binding domain-
containing protein 2 
Q8IV50 S24 
MAP7 domain-containing protein 1 Q3KQU3 S544 
Microtubule-associated protein 1A P78559 S384/T2655 
Microtubule-associated protein 1B P46821 S2271 
Microtubule-associated protein 1S Q66K74 S759 
Microtubule-associated protein 2 P11137 T1631 
Microtubule-associated protein tau P10636 T529/S579 
Monoglyceride lipase Q99685 S301 
N-alpha-acetyltransferase 10 P41227 S205 
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Neurofilament medium polypeptide P07197 S558 
NSFL1 cofactor p47 Q9UNZ2 S114 
Nuclear receptor coactivator 5 Q9HCD5 S6 
Nucleolar and coiled-body phosphoprotein 1 Q14978 S264 
Oxidation resistance protein 1 Q8N573 S7 
Paralemmin-1 O75781 T145/S162 
Phosphoglycerate kinase 1 P00558 Y76 
Plakophilin-4 Q99569 S776 
Plectin Q15149 S2039 
Potassium voltage-gated channel subfamily A member 2 P16389 S441 
Protein bassoon Q9UPA5 S1362 
Protein cordon-bleu O75128 S235 
Protein ELFN1 P0C7U0 S461 
Protein kinase C alpha type P17252 S226 
Protein kinase C epsilon type Q02156 S346 
Protein phosphatase 1 regulatory subunit 1A Q13522 S6 
Rabankyrin-5 Q9P2R3 S861 
Ral GTPase-activating protein subunit alpha-1 Q6GYQ0 S740 
Ras-specific guanine nucleotide-releasing factor 2 O14827 S848 
Reticulon-1 Q16799 T300 
Serine/arginine-rich splicing factor 5 Q13243 S233 
Serine/arginine repetitive matrix protein 1 Q8IYB3 S675 
Signal-induced proliferation-associated 1-like protein 2 Q9P2F8 S194 
SLIT-ROBO Rho GTPase-activating protein 3 O43295 S1068 
Sorbin and SH3 domain-containing protein 1 Q9BX66 T497 
Spectrin alpha chain, non-erythrocytic 1 Q13813 S1031 
Spectrin beta chain, non-erythrocytic 4 Q9H254 S2254 
Synapsin-1 P17600 S568 
Synaptophysin P08247 Y81 
Synaptopodin Q8N3V7 S754 
Syntaphilin O15079 S200/S204 
T-complex protein 1 subunit delta P50991 T239 
Tau-tubulin kinase 1 Q5TCY1 S456 
TBC1 domain family member 10B Q4KMP7 S678 
Thy-1 membrane glycoprotein P04216 S24 
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Tight junction protein ZO-1 Q07157 S1278 
Tight junction protein ZO-2 Q9UDY2 S266 
Tripartite motif-containing protein 2 Q9C040 S10 
Tuberin P49815 S939 
Ubiquitin-associated protein 2-like Q14157 S467 
Ubiquitin carboxyl-terminal hydrolase CYLD Q9NQC7 S399 
UHRF1-binding protein 1-like A0JNW5 S989 
Uncharacterized protein C9orf172 C9J069 S484 
Uncharacterized protein KIAA1211-like Q6NV74 S653 
Voltage-dependent P/Q-type calcium channel subunit 
alpha-1A 
O00555 S2463 
WAS/WASL-interacting protein family member 3 A6NGB9 T208 
Zinc finger CCCH domain-containing protein 18 Q86VM9 S534 
Zinc finger Ran-binding domain-containing protein 2 O95218 S153 
 
(B) 
Protein Accession Phosphosite/s 
2',3'-cyclic-nucleotide 3'-phosphodiesterase P09543 S64/S327 
60 kDa heat shock protein, mitochondrial P10809 S70 
Ankyrin repeat domain-containing protein 27 Q96NW4 S634 
AP-3 complex subunit beta-2 Q13367 S272 
Arf-GAP with GTPase, ANK repeat and PH domain-
containing protein 1 
Q9UPQ3 S421 
Band 4.1-like protein 2 O43491 S550 
Caskin-1 Q8WXD9 S1257 
Catenin alpha-2 P26232 S654 
E3 ubiquitin-protein ligase HUWE1 Q7Z6Z7 S2362 
Guanine nucleotide-binding protein G(I)/G(S)/G(O) 
subunit gamma-2 
P59768 T52 
Hepatocyte cell adhesion molecule Q14CZ8 S377 
Heterogeneous nuclear ribonucleoprotein U-like protein 
2 
Q1KMD3 T165 
Huntingtin-interacting protein 1 O00291 S320 
Inactive ubiquitin carboxyl-terminal hydrolase 54 Q70EL1 S481 
Microtubule-associated protein 1B P46821 S970/S995/S1322 
Microtubule-associated protein 4 P27816 S507/T521 
Microtubule-associated protein 6 Q96JE9 S812 
Nuclear receptor-binding protein Q9UHY1 S2 
Nucleolar protein 56 O00567 S569 
Pecanex-like protein 3 Q9H6A9 S1955 
Potassium voltage-gated channel subfamily KQT 
member 2 
O43526 S472 
Protein kinase C gamma type P05129 T655 
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Rho GDP-dissociation inhibitor 1 P52565 S24 
Rho guanine nucleotide exchange factor 7 Q14155 S249 
Serrate RNA effector molecule homolog Q9BXP5 S4 
Transcription intermediary factor 1-beta Q13263 S594 
Transmembrane protein 229A B2RXF0 S4 
Tumor protein D52 P55327 S144 
UV excision repair protein RAD23 homolog A P54725 S123 
Vinculin P18206 S290/S346 
Vinexin O60504 S545 
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Table IV: Phosphorylation sites of selected proteins in ARTAG 
    Isoform Name Peptide Sequence      Position Peptide      Position Protein 
 
Glial fibrillary acidic protein RSYVSSGEMMVGGLAPGR 3 14 
Glial fibrillary acidic protein DGEVIKESK 8 424 
Glial fibrillary acidic protein RITSAAR 4 8 
Glial fibrillary acidic protein FASYIEK 3 82 
Isoform Tau-C of Microtubule-associated protein tau TPSLPTPPTR 1 212 
Isoform Tau-C of Microtubule-associated protein tau IGSTENLK 3 262 
Potassium voltage-gated channel subfamily A member 2 IPSSPDLK 4 441 
cAMP-dependent protein kinase catalytic subunit alpha TWTLCGTPEYLAPEIILSK 3 198 
cAMP-dependent protein kinase catalytic subunit alpha GPGDTSNFDDYEEEEIRVSINEK 19 339 
Catenin beta-1 RTSMGGTQQQFVEGVR 3 552 
Catenin beta-1 RLSVELTSSLFR 3 675 
Microtubule-associated protein 1A  STTSQVTPAEEK 7 2655 
Microtubule-associated protein 1B SKPLAASPKPAGLK 7 2271 
Tuberin STSLNERPK 3 939 
Aquaporin-4 AAQQTKGSYMEVEDNR 5 273 
Protein phosphatase 1 regulatory subunit 1A MEQDNSPRK 6 6 
Calcium/calmodulin-dependent protein kinase type II 
subunit gamma STVASMMHR 1 276 
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide 
phosphodiesterase 1C RSSLNSISSSDAK 3 469 
Tau-tubulin kinase 1 VNSPESER 3 456 
C-Jun-amino-terminal kinase-interacting protein 3 SNTPTSSVPSAAVTPLNESLQPLGDYGVGSK 3 275 
Catenin delta-2 ATGQSFSQGTTSR 5 201 
Catenin delta-2 GGSAPEGATYAAPR 3 285 
Neurofilament medium polypeptide EGSSEKEEGEQEEGETEAEAEGEEAEAKEEK 3 558 
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